ADCs at $20B: The Modality That Ate Oncology

The antibody-drug conjugate market has grown from $16B in 2025 to over $20B in 2026, fueled by Gilead's $5B Tubulis acquisition and Lilly's CrossBridge Bio deal. A deep dive into next-gen linker-payload chemistry, dual-payload designs, and which tumor types remain white space.